Ran Wei

Director of Research Development

About

Ph.D. Cell Biologist & R&D Director driving next-generation immunotherapies at Shanghai Immuxell Biotech. Expert in end-to-end TCR-T/CAR-T development, successfully advancing KRAS-targeting programs from discovery through IND approval to Phase I trials. Pioneered in vivo targeted viral vectors (LV/RV) and engineered TCR-based biologics (TCEs, fusions). Built robust platforms: stable producer cell lines, novel analytical assays, and innate immune cell engineering. Secured 8+ PCT/national patents and FDA DMF filings. Previously at Polaris Biology, led neoantigen/TCR biologics platforms and contributed to China's first proprietary mass cytometry system, supporting a CD19 CAR-T to NMPA approval. Proven in translating complex science into clinical impact.

Country

China

City

Pudong

Industry

Biotechnology

Skill

项目管理, 项目制定, 项目控制, 新药发现, 药品开发, 项目创立, T cells, TCR Discovery, Virology, Next-Generation Sequencing (NGS), Innate Immunity, molecule labeling, Immuno-phenotyping, multiplex immune assays , Neoantigen Discovery, TCR Engineering, TCR Biologics, Neoantigen, Cell Biology, Cell Signaling

Experience

Director of Research Development

ImmuXell Biotech

2023-12 - 2025-10 · 1 yr 11 mos

Pudong, Shanghai, China

◆ TCR-T Cell Therapy. ◆ In Vivo CAR-T/TCR-T. ◆ T Cell-Engaging Biologics.

R&D Director, Drug Discovery

Polaris Biology

2019-12 - 2023-11 · 4 yrs

Pudong, Shanghai, China

◆ Establishment of a Novel Neoantigen Discovery Platform. ◆ Establishment of TCR Discovery and Validation Platform. ◆ Development of TCR Biologics.

Senior Research Scientist

Polaris Biology

2018-1 - 2019-12 · 2 yrs

Pudong, Shanghai, China

◆ Development of Mass Cytometry System. ◆ Development of Reagents for Mass Cytometry. ◆ Research Applications and Clinical Collaboration Projects in Mass Cytometry

Education

Chinese Academy of Sciences

Cell Biology

2013 - 2018 · 5 yrs

Ph.D. in Cell Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Science, in the Interdisciplinary Research Center of Biology and Chemistry (IRCBC), under Prof. Junying Yuan (Founder and Director of IRCBC, Fellow of the National Academy of Sciences). My research focused on inflammation, cellular innate immunity, the mechanism of apoptosis, necroptosis and ferroptosis. Publications: 1. K. Dong, R. Wei, T. Jin, M. Zhang, J. Shen, H. Xiang, B. Shan, J. Yuan and Y. Li. HOIP modulates the stability of GPx4 by linear ubiquitination. Proc Natl Acad Sci U S A.2022. 2. R. Wei., L.W. Xu, J. Liu, Y. Li, P. Zhang, B. Shan, X. Lu, L. Qian, Z. Wu, K. Dong, H. Zhu, L. Pan, J. Yuan, and H. Pan. 2017. SPATA2 regulates the activation of RIPK1 by modulating linear ubiquitination. Genes Dev. 2017. 3. Xu, D., Zhang, T., Xiao, J., Zhu, K., Wei, R., Wu, Z.,Yuan, J（2015）. Modification of BECN1 by ISG15 plays a crucial role in autophagy regulation by type I IFN/interferon. Autophagy. 2015.

Nanjing University

Biology

2009 - 2013 · 4 yrs

Investigating Novel 4,5-dihydro-1H-pyrazole niacinamide derivatives as BRAF inhibitors. I cooperated with 3 partners to design and synthesis a series of novel 4,5-dihydropyrazole derivatives as potential V600E mutant BRAF (Highly Pathogenic in cancers) inhibitors. And pick up 1 compound bearing the best bioactivity in melanoma cells. Publication: Li, C., Li, Q., Yan, L., Sun, X., Wei, R., Gong, H., & Zhu, H. (2012). Synthesis, biological evaluation and 3D-QSAR studies of novel 4,5-dihydro-1H-pyrazole niacinamide derivatives as BRAF inhibitors. Bioorganic & Medicinal Chemistry. 2012.